[{"orgOrder":0,"company":"Biovaxys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioVaxys Announces 96.4 Percent Positive Antibody Immune Response Results from an In Vivo Murine Model Study of Its SARS-CoV-2 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Biovaxys","sponsor":"WuXi Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biovaxys Inks Agreement With WuXi Biologics to Synthesize Proteins for Its Sars-CoV-2 Vaccine and Covid-T\u2122 Immunodiagnostic Programs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Bio Elpida","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioVaxys and BioElpida Sign Definitive Exclusive Agreement To Begin Ovarian Cancer Vaccine Bioproduction","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioVaxys and Bioproduction Partner Bio Elpida Begin Construction of GMP Facility to Produce Clinical Supply","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Bio Elpida","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioVaxys Cancer Vaccine Manufacturing Partner Bio Elpida Reaches Bioproduction Milestone","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioVaxys Files US Patent Application for Pan-Sarbecovirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Biovaxys","sponsor":"The Ohio State University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioVaxys Announces Bioproduction of BVX-1021 for its Pan-Sarbecovirus Program in Collaboration with The Ohio State University","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Deaconess Research Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioVaxys Enters Critical Tumor Cell Supply Agreement with Deaconess Research Institute for BVX-0918 Bioproduction","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Procare Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"International Patent Application Filed for Cervical Cancer Vaccine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Bio Elpida","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Manufacturing Partner BioElpida Completes Next Phase of BVX-0918 GMP Production for EU Clinical Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Hospices Civils de Lyon","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Merck Millipore","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biovaxys Announces Completed Synthesis of Its Pan-sarbecovirus Vaccine Candidate and Launch of in Vivo Animal Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Biovaxys","sponsor":"The Ohio State University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioVaxys Sarbecovirus Vaccine Interim Data Excellent Emerging Safety & Tolerability Profile with BVX-1021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Biovaxys","sponsor":"ProCare Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioVaxys and Procare Health Execute US Distribution Agreement for Papilocare Gel and Oral Immunocaps","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Biovaxys","pharmaFlowCategory":"D","amount":"$25.7 million","upfrontCash":"$25.7 million","newsHeadline":"BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Biovaxys
The acquisition supplements BioVaxys' existing cancer vaccine portfolio with the addition of DPX-Survivac (maveropepimut-S), a DPX™-formulated cancer vaccine that delivers antigenic peptides from survivin, a cancer antigen commonly overexpressed in advanced cancers.
Papilocare (hyaluronic acid) vaginal gel is the first treatment that has been scientifically proven to have a very high success rate in eliminating not only the human papiloma virus (HPV), but also precancerous lesions of the cervix.
BVX-1021 is hapten-modified recombinant S1 subunit of the spike protein from the SARS1 virus, whereas BVX-0320, is a hapten-modified recombinant S1 subunit of the spike protein from SARS-CoV-2 ("SARS2"), the virus which causes Covid-19.
BVX-1021 using a new batch of recombinant SARS-1 protein from the supplier that screened out the extraneous protein aggregate, has been synthesized using the purified SARS1 protein, OSU is now able to complete the neutralizing antibody studies.
BVX-0918A, BioVaxys’s cancer vaccines are created by extracting a patient’s own cancer cells, chemically treating them with a hapten, and re-injecting them into the patient to induce an immune response to proteins which are otherwise not immunogenic.
BioVaxys expects to be able to prepare its regulatory submission for a EU Phase I study of BVX-0918 in Stage III/Stage IV ovarian cancer near the end of this year, with vaccine supply for the planned clinical study available early May 2022.
BioVaxys’s cancer vaccine BVX-0918C, created by extracting a patient’s own cancer cells, chemically treating them with a hapten, and re-injecting them into patient to induce an immune response to proteins which are otherwise not immunogenic.
Access to ovarian cancer tumor cells is a critical step enabling BioVaxys to validate the manufacturing process for BVX-0918, the Company's autologous haptenized tumor cell vaccine for late-stage ovarian cancer.
BVX-1021 is the subject of an ongoing research collaboration between The Ohio State University and BioVaxys, announced in December 2021, that is evaluating the Company's novel approach for a "universal vaccine" that can treat a broad range of sarbecoviruses.
Biovaxys intends to leverage its haptenized viral protein vaccine platform to induce immunity against all or most sarbecoviruses by immunizing people, with a novel vaccine composed of the dinitrophenyl (“DNP”)-modified S-spike protein of SARS-CoV-1.
Lead Product(s):
Dinitrophenyl Modified S-spike Protein of SARS-CoV-1